Corticosteroid switch after progression on abiraterone acetate plus prednisone.
Abiraterone Acetate
/ administration & dosage
Adrenal Cortex Hormones
/ administration & dosage
Aged
Androstenes
/ administration & dosage
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Dexamethasone
/ administration & dosage
Humans
Male
Middle Aged
Patient Selection
Prednisolone
/ administration & dosage
Prednisone
/ administration & dosage
Prostatic Neoplasms, Castration-Resistant
/ drug therapy
Treatment Outcome
Abiraterone
Dexamethasone
Prednisone
Switch
Journal
International journal of clinical oncology
ISSN: 1437-7772
Titre abrégé: Int J Clin Oncol
Pays: Japan
ID NLM: 9616295
Informations de publication
Date de publication:
Feb 2020
Feb 2020
Historique:
received:
30
07
2019
accepted:
04
11
2019
pubmed:
11
11
2019
medline:
12
6
2020
entrez:
10
11
2019
Statut:
ppublish
Résumé
Abiraterone acetate plus prednisone is approved in metastatic castration-resistant prostate cancer. There is some evidence in favour of the steroid switch from prednisone to dexamethasone in patients who progressed whilst on abiraterone acetate plus prednisone or prednisolone. The aim of this review is to discuss the results from the clinical studies available, examining potential mechanisms of action and patient selection criteria for this treatment option. A total of four studies were evaluated. Among possible eligibility criteria for steroid switch, we found: PSA progression without any radiological or clinical progression during abiraterone acetate + prednisone; no high-grade adverse events related to CYP-17 inhibition; and unfitness for chemotherapy or radium-223. Although large randomized prospective trials are warranted, steroid switch seems to offer a good option for certain patients treated with abiraterone acetate plus prednisone or prednisolone.
Identifiants
pubmed: 31705219
doi: 10.1007/s10147-019-01577-w
pii: 10.1007/s10147-019-01577-w
doi:
Substances chimiques
Adrenal Cortex Hormones
0
Androstenes
0
Dexamethasone
7S5I7G3JQL
Prednisolone
9PHQ9Y1OLM
Abiraterone Acetate
EM5OCB9YJ6
abiraterone
G819A456D0
Prednisone
VB0R961HZT
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
240-246Références
N Engl J Med. 2013 Jan 10;368(2):138-48
pubmed: 23228172
N Engl J Med. 1995 May 25;332(21):1393-8
pubmed: 7723794
Oncol Lett. 2010 Jan;1(1):73-79
pubmed: 22966259
Nat Med. 2000 Jun;6(6):703-6
pubmed: 10835690
J Natl Cancer Inst. 2001 Nov 21;93(22):1739-46
pubmed: 11717335
Cancers (Basel). 2017 Jun 12;9(6):null
pubmed: 28604629
Br J Cancer. 2018 Oct;119(9):1052-1059
pubmed: 30131546
J Urol. 2006 Jan;175(1):27-34
pubmed: 16406864
J Clin Endocrinol Metab. 1982 Feb;54(2):332-42
pubmed: 6274900
Clin Cancer Res. 2006 May 15;12(10):3003-9
pubmed: 16707595
Crit Rev Oncol Hematol. 2016 May;101:12-20
pubmed: 26971992
Lancet Oncol. 2012 Oct;13(10):983-92
pubmed: 22995653
Cell. 2013 Dec 5;155(6):1309-22
pubmed: 24315100
Ann Oncol. 2015 Aug;26(8):1589-604
pubmed: 26041764
Eur Urol. 2015 Apr;67(4):673-9
pubmed: 25457497
Mol Cell Endocrinol. 2012 Sep 5;360(1-2):68-75
pubmed: 21986558
Expert Rev Anticancer Ther. 2014 Oct;14(10):1135-40
pubmed: 25135334
Invest New Drugs. 2018 Dec;36(6):1110-1115
pubmed: 30345466
Lancet Oncol. 2015 Feb;16(2):152-60
pubmed: 25601341
Prostate. 2003 Jul 1;56(2):106-9
pubmed: 12746834
Oncologist. 2015 May;20(5):e13
pubmed: 25888271
BJU Int. 2019 Feb;123(2):300-306
pubmed: 30099821
Cancer Res. 2012 May 1;72(9):2176-82
pubmed: 22411952
Invest New Drugs. 2018 Dec;36(6):1133-1137
pubmed: 30083960
Urol Oncol. 2017 May;35S:S1-S13
pubmed: 28283376
Horm Metab Res. 2004 Jun;36(6):423-9
pubmed: 15241735
CA Cancer J Clin. 2018 Jan;68(1):7-30
pubmed: 29313949
Cancer. 2000 Dec 15;89(12):2570-6
pubmed: 11135218
Cancer Res. 2009 Jun 15;69(12):4937-40
pubmed: 19509232
J Biol Chem. 2002 Mar 1;277(9):7076-85
pubmed: 11751884
N Engl J Med. 2011 May 26;364(21):1995-2005
pubmed: 21612468
Endocr Pract. 2001 Jan-Feb;7(1):11-5
pubmed: 11250762
World J Clin Oncol. 2015 Oct 10;6(5):99-103
pubmed: 26468445
Lancet. 2016 Mar 19;387(10024):1163-77
pubmed: 26719232
Br J Cancer. 2014 Dec 9;111(12):2248-53
pubmed: 25314055
Endocr Relat Cancer. 2016 Nov;23(11):T85-T108
pubmed: 27645052
J Steroid Biochem Mol Biol. 2009 Aug;116(1-2):29-36
pubmed: 19406240